BioAxone BioSciences Expands Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors
Retrieved on:
Monday, December 16, 2019
Biotechnology, Pharmaceutical, Genetics, Health, Benign neoplasms, Cavernous hemangioma, Medicine, Cavernous sinus, CCM, Clinical medicine, Health, Draft:Cerebral Cavernous Malformation, Central nervous system cavernous hemangioma, Biotechnology, Pharmaceutical, Genetics, Health, Benign neoplasms, Cavernous hemangioma, Medicine, Cavernous sinus, CCM, Clinical medicine, Health, Draft:Cerebral Cavernous Malformation, Central nervous system cavernous hemangioma
The notice refers to a critical patent application (US 15/988,736) covering the oral drug candidate in development, BA-1049.
Key Points:
- The notice refers to a critical patent application (US 15/988,736) covering the oral drug candidate in development, BA-1049.
- Data from a recent clinical study indicates that BA-1049 has promise as a therapeutic agent for the treatment of cavernous angioma (CA), also called cerebral cavernous malformation (CCM).
- CA is a serious genetic disease with no current treatment available other than surgical removal of the brain lesions.
- We are very pleased with this expansion of our patent estate for BA-1049, said Lisa McKerracher, PhD, CEO, BioAxone BioSciences.